Pulmonary fibrosis, the progressive scarring of lung tissue, cannot always be prevented, especially when genetics play a role. But many of the known triggers are avoidable, and reducing your exposure to them meaningfully lowers your risk. Current smokers face a 66% higher risk of developing idiopathic pulmonary fibrosis (IPF) compared to people who have never smoked, according to a nationwide cohort study of over 23 million people published in Thorax. That single statistic captures the central theme of prevention: the lungs are vulnerable to repeated injury, and most protective strategies come down to limiting that injury.
Quit Smoking or Never Start
Smoking is the most well-established modifiable risk factor for pulmonary fibrosis. In the same large Korean cohort study, even former smokers carried a 42% higher risk than never-smokers, though their risk was significantly lower than that of people still smoking. Current smokers had a 17% higher risk than former smokers after adjusting for age, sex, alcohol use, physical activity, income, and body weight. The data doesn’t pinpoint an exact timeline for when risk levels off after quitting, but the gap between current and former smokers makes a clear case: stopping sooner is better than stopping later, and stopping later is better than not stopping at all.
Reduce Workplace Dust and Fiber Exposure
Occupational exposure to fine particles is one of the most preventable causes of lung scarring. Silica dust, asbestos fibers, coal dust, and organic materials like cotton and grain can all damage the delicate tissue between the air sacs in your lungs over years of repeated inhalation. Federal agencies set strict limits on how much of these substances workers can breathe. For asbestos, the limit is 0.1 fiber per cubic centimeter of air over an eight-hour shift, with a short-term ceiling of 1 fiber per cubic centimeter over any 30-minute window. For coal mine dust, the recommended limit is 1 milligram per cubic meter over a 10-hour shift.
If you work in mining, construction, textile manufacturing, woodworking, or agriculture, wearing proper respiratory protection is not optional. Employers are required to provide appropriate respirators, but you should also confirm that dust control measures like ventilation and wet-cutting are in place. The damage from these exposures accumulates silently over years, so consistent protection matters more than occasional caution.
Avoid Organic Allergens That Cause Lung Inflammation
Hypersensitivity pneumonitis is a specific type of lung inflammation triggered by inhaling organic particles, and when it becomes chronic, it causes irreversible fibrosis. The most common culprits include proteins in bird feathers and droppings (sometimes called bird fancier’s lung), mold growing on hay, straw, and grain (farmer’s lung), and fungi or bacteria breeding in humidifiers, heating systems, and air conditioning units (humidifier lung).
The damage from chronic hypersensitivity pneumonitis cannot be reversed, so avoidance is the only reliable prevention. If you keep birds, clean enclosures with proper ventilation and wear a mask. If you work with hay or grain, use respiratory protection consistently. At home, clean humidifiers regularly, replace HVAC filters on schedule, and address any visible mold promptly rather than ignoring it. If you’ve already been diagnosed with hypersensitivity pneumonitis, complete removal of the allergen source is the single most important step to prevent progression to fibrosis.
Improve Indoor Air Quality
The air inside your home can carry risks you don’t see or smell. Burning wood, coal, or other solid fuels for heat or cooking releases fine particulate matter (PM2.5) that often exceeds health-based air quality standards. Globally, household burning of biomass fuels is the largest source of indoor air pollution, particularly in lower-income countries. Even in wealthier nations, wood-burning stoves and fireplaces contribute to chronic lung irritation.
If you heat with wood, make sure your stove meets current emissions standards and that your home is adequately ventilated. Upgrading to a cleaner-burning stove or switching to a non-combustion heat source reduces particulate exposure substantially. Secondhand cigarette smoke is another major indoor pollutant that damages lung tissue over time. Radon, a naturally occurring radioactive gas that seeps into buildings through foundation cracks, is primarily linked to lung cancer rather than fibrosis, but it contributes to the overall burden of lung injury. Inexpensive home radon test kits are widely available, and mitigation systems can reduce high levels effectively.
Know Which Medications Carry Lung Risk
Dozens of commonly prescribed medications can cause drug-induced lung disease, and in some cases that includes fibrosis. The ones most frequently implicated are certain chemotherapy drugs (particularly bleomycin, carmustine, busulfan, and cyclophosphamide), the heart rhythm medication amiodarone, and the antibiotic nitrofurantoin, which in its chronic form can cause pulmonary fibrosis. Methotrexate, used for autoimmune conditions and some cancers, is another well-known offender.
You can’t always avoid these medications, as sometimes they’re the best or only option for a serious condition. What you can do is stay aware. If you’re on bleomycin, periodic lung function tests are considered useful for catching early toxicity. The same monitoring is sometimes done for amiodarone and methotrexate, though the evidence for routine testing with those drugs is less clear-cut. The practical takeaway: if you develop a new dry cough, unexplained shortness of breath, or declining exercise tolerance while taking any long-term medication, bring it up with your doctor promptly. Early detection of drug-induced lung changes allows for dose adjustments or medication switches before permanent scarring sets in.
Protect Your Lungs During Cancer Treatment
Radiation therapy to the chest, particularly for breast cancer, can damage surrounding lung tissue and lead to fibrosis. Modern radiotherapy techniques have made this considerably less common. Three-dimensional conformal radiation, intensity-modulated radiation therapy, and volumetric-modulated arc therapy all shape the radiation beam more precisely to the tumor, reducing the dose that reaches healthy lung tissue.
Additional lung-sparing strategies have become routine at many treatment centers. Deep inspiration breath-hold, where you take a deep breath and hold it during treatment, moves the chest wall away from the heart and lungs, reducing their radiation exposure. Proton beam therapy offers even more precision by depositing its energy directly in the tumor with minimal exit dose beyond the target. If you’re facing chest radiation, asking your oncology team about these techniques is reasonable. The choice of technique depends on your specific tumor location and anatomy, but awareness of these options helps you participate in that conversation.
Monitor After Severe Lung Infections
Severe pneumonia, particularly from COVID-19, can leave lasting lung scarring in some patients. When significant inflammation is present during recovery, steroid medications like prednisone are commonly used to tamp down the immune response before it causes permanent damage. Antifibrotic medications already approved for other forms of pulmonary fibrosis are being studied in clinical trials for post-COVID lung disease, though they aren’t yet standard treatment for that purpose.
If you’ve been hospitalized for severe pneumonia or acute respiratory distress syndrome from any cause, follow-up imaging and lung function testing in the months afterward can catch early fibrotic changes. Not everyone who has a severe lung infection develops lasting scarring, but those who do benefit from early identification and management.
Understand Your Genetic Risk
Some people carry genetic variants that increase their susceptibility to pulmonary fibrosis, even without obvious environmental triggers. The most studied is a variant in the MUC5B gene, which was found at a frequency of nearly 40% in IPF patients compared to 12% in healthy controls in one study, representing roughly a fivefold increase in disease susceptibility. Variants in the TERT gene, involved in maintaining the protective caps on chromosomes, have also been linked to IPF.
Research on first-degree relatives of IPF patients found that 14% of at-risk relatives had early signs of interstitial lung changes on high-resolution CT scans at a mean age of 50, and they carried the MUC5B variant at roughly twice the rate of the general population. If you have a parent or sibling with pulmonary fibrosis, this family history is worth mentioning to your doctor. Genetic testing for these variants exists, though it’s not yet part of routine screening guidelines. The value lies in heightened awareness: people with a genetic predisposition benefit most from aggressively avoiding every other risk factor on this list.
Catch Early Signs Before Scarring Progresses
Pulmonary fibrosis is easiest to slow when caught early, and one of the earliest detectable signs is a specific sound your doctor can hear with a stethoscope. Called “Velcro-type” crackles, these brief, explosive popping sounds at the base of both lungs resemble the noise of separating Velcro strips. Research has confirmed that even early-stage fibrotic changes, such as ground-glass opacities and fine reticular patterns on imaging, produce these distinctive crackles. Any degree of abnormal fibrotic tissue deposited in the lungs can cause the collapse of tiny distal airways that generates the sound.
International guidelines recommend suspecting pulmonary fibrosis in anyone with these bilateral inspiratory crackles, making a simple stethoscope exam a low-cost early warning system. If you have risk factors for pulmonary fibrosis, including smoking history, occupational exposures, family history, or long-term use of high-risk medications, a persistent dry cough or gradually worsening breathlessness warrants a visit where your doctor listens carefully to your lung bases. Early detection opens the door to treatments that can slow progression before significant lung function is lost.
The Role of Vitamin D
Vitamin D deficiency has been linked to pulmonary fibrosis in a growing body of research. The vitamin plays a role in regulating inflammation, controlling cell growth, and maintaining the balance of the structural matrix in lung tissue. In laboratory studies, vitamin D has been shown to lower levels of several inflammatory signaling molecules and to block a key chemical pathway (TGF-beta signaling) that drives the transformation of normal lung cells into scar-producing cells. It also appears to promote the activity of regulatory immune cells that help keep inflammation in check.
None of this means vitamin D supplements will prevent pulmonary fibrosis outright. The research is largely mechanistic, showing how vitamin D could protect lung tissue rather than proving it does so in large human populations. Still, maintaining adequate vitamin D levels through sunlight, diet, or supplementation is a low-risk measure that supports lung health alongside its well-known benefits for bones and immune function.